Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.
CEO and Co-founder
Mike’s career spans more than 30 years in life sciences working for a range of companies in senior management and leadership roles. Trained as a microbiologist, Mike began his career during the early years of the biotechnology industry working in the technical field before transitioning into sales, marketing, business management and executive director roles. His passion is in translating life sciences into life products including biocatalysts, biologics, vaccines and stem cells, working for and advising large, medium and start-up companies including ICI, Zeneca, Avecia Biologics, Chirex and spin-out investor-backed enterprises.